Component
Plasma duloxetine exposure
Plasma duloxetine exposure. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Fluvoxamine increased oral duloxetine AUC by 460% and peak concentration by 141% in the clinical study.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/dim-research/18307373.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149", "start_char": 0, "end_char": 2879, "text_sha256": "2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149"}
- experimental_model
- Enzyme phenotyping and clinical drug-interaction studies
- exposure
- Fluvoxamine with oral or intravenous duloxetine
- limitations
- The clinical exposure change was caused by fluvoxamine, not DIM. The study tests inhibition, not the inverse size of induction.
- nutrient_topic
- Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. · 3,3'-Diindolylmethane / DIM
- organism
- Human enzyme systems and healthy adults
- plain_language
- Blocking metabolism increased exposure; this measured result must not be relabeled as a DIM study.
- primary_references
- [dim-p18307373] In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. (2008). https://pubmed.ncbi.nlm.nih.gov/18307373/ DOI: 10.2165/00003088-200847030-00005
- tissue_or_cell_type
- Duloxetine metabolism and exposure
Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17) · lines 805–816
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Enzyme phenotyping and clinical drug-interaction studies · source_derived_draft · unverified_draft
### dim-duloxetine-inhibition Fluvoxamine increased oral duloxetine AUC by 460% and peak concentration by 141% in the clinical study. Condition category: normal nutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. plain_language: Blocking metabolism increased exposure; this measured result must not be relabeled as a DIM study. organism: Human enzyme systems and healthy adults tissue_or_cell_type: Duloxetine metabolism and exposure experimental_model: Enzyme phenotyping and clinical drug-interaction studies limitations: The clinical exposure change was caused by fluvoxamine, not DIM. The study tests inhibition, not the inverse size of induction. exposure: Fluvoxamine with oral or intravenous duloxetine evidence_span: {"source_cache": "artifacts/dim-research/18307373.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149", "start_char": 0, "end_char": 2879, "text_sha256": "2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149"} [dim-p18307373] In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. (2008). https://pubmed.ncbi.nlm.nih.gov/18307373/ DOI: 10.2165/00003088-200847030-00005
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.